Philips Expands Imaging Capabilities on Handheld Ultrasound Device
In addition to newly added advances with hemodynamic assessment and obstetric measurements, Lumify also offers a B-line quantification tool and AI-enhanced algorithms that may bolster ultrasound lung imaging in severe COVID-19 cases.
Building upon the applications of its handheld, point-of-care ultrasound device Lumify, Philips noted the modality now features advanced hemodynamic assessment as well as obstetric measurement capabilities.
The addition of Pulse Wave Doppler to Lumify enables clinicians to differentiate between arterial and venous blood flow and quantify hemodynamic function. Philips said the hemodynamic measurement capabilities of Lumify can facilitate timely interventions in cardiology and emergency medicine settings. The use of obstetric measurements may also aid in identifying high-risk pregnancies, according to the company.
“With the addition of Pulse Wave Doppler and enhanced obstetric measurements, we have increased the number of markers on which diagnoses can be made to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real time,” noted Matthijs Groot Wassink, general manager of point of care ultrasound at Philips.
Noting the key role of lung ultrasound in diagnosing pneumonia, a common complication of COVID-19, Philips maintained that Lumify is the only point-of-care ultrasound device that features artificial intelligence (AI)-enhanced B-line quantification. The company said the ability of this technology to assess B-lines in lung fluid may be beneficial for patients with severe cases of COVID-19 infection.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
